Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.
Sodium-glucose cotransporter-2 inhibitors recommended for HF with reduced, mildly reduced ejection fraction.
Aspirin use was associated with increased risk for incident heart failure among individuals with or without a history of cardiovascular disease
Findings for both out-of-hospital and in-hospital ST-segment elevation myocardial infarction.
46 percent of those diagnosed in acute care had potential heart failure symptoms in previous six months.
Increase of 585 percent seen in methamphetamine-associated cardiomyopathy/heart failure hospitalizations from 2008 to 2018
Increased rates of cancer seen among women and men and for cancer at multiple sites, including lip, oral cavity, pharynx, respiratory organs